邱源旺,男,教授,主任医师,医学博士,南京医科大学、南通大学及江南大学硕士生导师,江南大学博士后联合培养导师,江南大学附属无锡五院副院长。
现任中国中西医结合学会第五届传染病专业委员会委员、中华医学会感染病学分会第十一届委员会肝炎学组委员、中华医学会感染病学分会肝衰竭与人工肝专家委员会委员、江苏省医学会感染病学分会常务委员、江苏省医院协会第六届传染病医院分会常务委员、江苏省中西医结合学会肝病专业委员会委员、江苏省第三届艾滋病专业委员会委员、江苏省医师协会感染科医师分会委员、无锡市医学会感染病学专业委员会主任委员、无锡市感染性疾病质控中心主任、无锡市医院协会院感专业委员会副主任委员;《国际病毒学杂志》、《中西医结合肝病杂志》、《现代医药杂志》编委,参与全国普通高等院校五年制临床医学专业规划教材《传染病学》编写。
主要从事感染性疾病临床诊治及病毒性肝炎基础和临床研究工作。先后参与国家“十一五、十二五、十三五”艾滋病和病毒性肝炎等重大传染病防治”科技重大专项子课题研究及国家重点研发计划“新冠疫情临床监测预警体系构建与应用研究”项目,主持省市级课题8项,研究成果已在J Infection(IF 38.637)、Emerg Microbes Infect、Front Immunol等国际和国内期刊发表论文40余篇,其中SCI收录论文15篇。获中国医院协会医院科技创新二等奖、江苏省医学新技术引进二等奖及无锡市科技进步三等奖各1项。荣获第五届江苏省“百名医德之星”、无锡市“十大医德标兵”。近3年指导硕士研究生5名、博士后1名。
代表性论文:
[1] Immunogenicity of a third dose of inactivated COVID-19 vaccine in people living with HIV-1, HBV, and tuberculosis during the Omicron variant epidemic: A cross-sectional study.JOURNAL OF INFECTION.2022,85 (4):e109-e111.(通讯作者)
[2] COVID-19: imbalanced cell-mediated immune response drives to immunopathology.Emerging microbes & infections.2022,11 (1):2393-2404.(通讯作者)
[3] CCL28 mucosal expression in SARS-CoV-2-infected patients with diarrhea in relation to disease severity.JOURNAL OF INFECTION.2021,82 (1):e19-e21(通讯作者)
[4] Characterizing COVID-19 severity, epidemiology and SARS-CoV-2 genotypes in a regional business hub of China.JOURNAL OF INFECTION.2021,82 (2):282-327.(通讯作者)
[5] Excessive Neutrophils and Neutrophil Extracellular Traps in COVID-19.Frontiers in immunology.2020,11:2063. (通讯作者)
[6] Acute-on-Chronic Liver Failure From Chronic-Hepatitis-B, Who Is the Behind Scenes.Frontiers in microbiology.2020,11:583423. (通讯作者)
[7] Develop and validate a novel online AIHI-nomogram to predict severe liver inflammation in patients with autoimmune hepatitis.Annals of Hepatology.2023,28 (6):101134. (通讯作者)
[8] IL-21 Is Associated With Virological Relapse of HBeAg Positive Chronic Hepatitis B After Discontinuance of Entecavir.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.2021,32 (2):178-186.(通讯作者)
[9] The efficacy and safety of entecavir in patients with advanced schistosomiasis co-infected with hepatitis B virus.INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES.2013,17 (8):e606-9.
[10] Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients.INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES.2016,43:43-48.